2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid | 112349-89-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide;3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid
• CAS: 112349-89-0
• 化学式: C20H29Cl2N3O10
• 分子量: 542.4
• InChiKey: DHXFPTYUHMKXTA-QPMNBHMGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.13
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  222
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• COMPOUNDS AND COMPOSITIONS FOR DRUG RELEASE
  申请人：INTERFACE BIOLOGICS, INC.

  公开号：US20160038651A1

  公开（公告）日：2016-02-11

  The invention relates to compounds that include biologically active agents (e.g., compounds according to any of formulas (I) and (I-A) that can be used for effective drug release, e.g., as coatings for medical devices. Use of these compounds in the coating of surfaces can allow for long-term drug release as well as imparting uniform coatings with little phase separation compared to, e.g., the parent biologically active agent.

  这项发明涉及包括生物活性剂（例如，根据任何公式（I）和（I-A）的化合物）的化合物，可用作有效的药物释放，例如，作为医疗器械的涂层。在表面涂层中使用这些化合物可以实现长期药物释放，并且与原生生物活性剂相比，可以实现均匀涂层且几乎没有相分离。
• Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase
  申请人：Schein Catherine H.

  公开号：US20090093519A1

  公开（公告）日：2009-04-09

  Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel.

  本发明描述了用于治疗和/或预防肠道液体丢失的小分子及其衍生物。还公开了使用所述分子及其衍生物治疗和/或预防与3′，5′-腺苷酸单磷酸增加水平相关的疾病的方法。本发明的特定组合物也是新颖的。
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• [EN] DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS<br/>[FR] DERIVES DIPHOSPHONATE D'AGENTS THERAPEUTIQUES
  申请人：ELIZANOR BIOPHARMACEUTICALS, INC.

  公开号：WO1996040190A1

  公开（公告）日：1996-12-19

  (EN) Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.(FR) Nouveaux agents chimiothérapeutiques convenant au traitement de maladies infectieuses telles que les parodontoses, certaines infections des voies urinaires, les calculs infectieux des voies urinaires et le cancer des os, et obtenus par l'association chimique d'un composé diphosphonate avec un agent thérapeutique agissant efficacement contre les maladies précitées.

  (中) 通过将二膦酸盐化合物与对牙周病、某些尿路感染、感染性尿路结石和骨癌等感染性疾病有效的治疗药物化学结合，获得了在治疗上具有实用价值的新型化疗药物。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。